Search for ways to improve the effectiveness of treatment of pulmonary tuberculosis patients with multiple resistance of mycobacterium tuberculosis to anti-tuberculosis drugs

Aim. To conduct a comparative study of the effectiveness of treatment of MDR-TB patients by using short-term and individual chemotherapy regimens and including the drug Cholecalciferol in the treatment complex.

Material and methods. The group of MDR-TB patients with a short-term treatment regimen included 40 patients, and 40 patients were included in the group of MDR-TB patients with an individual treatment regimen. Both observation groups were divided into two subgroups of patients with MDR-TB of the lungs (20 people from each group). In one group treatment included Cholecalciferol 300,000 U intramuscularly weekly (6-8 times in total) in the complex of the above treatment; comparison groups: patients with MDR-TB of the lungs (20 people from each group) received a complex of the above chemotherapy without the drug Cholecalciferol.

Results. In the group of patients with the inclusion of Cholecalciferol in a short-term treatment regimen, a favorable treatment outcome was noted in 100% of cases, while in the group of patients without Cholicalciferol - in 80% of cases. With an individual treatment regimen in the group of patients with the inclusion of Cholecalciferol, conversion by sputum culture also occurred in 100% of cases, while in the group of patients without Cholicalciferol - in 70% of patients.

Conclusion. Thus, the introduction of a new short-term chemotherapy regimen for MDR-TB patients has increased the effectiveness of their treatment. In two subgroups of MDR-TB patients with different chemotherapy regimens, who received injections of Cholecalciferol in the chemotherapy treatment plan, the effectiveness of treatment based on the results of the timing of the development of conversion by sputum culture was assessed as significantly higher than in the subgroups that did not receive vitamin D3.

1. Abdurakhimov A.A. Novye vzglyady na biologicheskie effekty i klinicheskoe deystvie vitamina D: obzor literatury [New Insights into the Biological Effects and Clinical Effects of Vitamin D: A Literature Review]. Vestnik Akademii Meditsinskikh Nauk Tadzhikistana - Bulletin of the Academy of Medical Sciences of Tajikistan, 2021, No. 3 (39), pp. 75-81.

2. Barsegyan L.K. Ergokaltsiferol i tazovaya bol, assotsiirovannaya ovarialnym endometriozom [Ergocalciferol and pelvic pain associated with ovarian endometriosis]. Issledovaniya i praktika v meditsine - Research and practice in medicine, 2018, No. 1 (5), pp. 19-21.

3. Belyaeva I.V. Vliyanie vitamina D na immunitet bolnykh aktivnymi formami tuberkuleza i sarkoidoza [Effect of vitamin D on immunity in patients with active forms of tuberculosis and sarcoidosis]. Detskaya meditsina Severo-Zapada - Children’s medicine of the North-West, 2018, No. 1 (7), pp. 39-44.

4. Bobokhodzhaev O.I. Dinamika razvitiya lekarstvennoy ustoychivosti pri tuberkulyoze v Respublike Tadzhikistan [Dynamics of Development of Drug Resistance in Tuberculosis in the Republic of Tajikistan]. Evraaziyskiy meditsinskiy nauchno-prakticheskiy zhurnal «Sino» - Eurasian medical scientific-practical journal “Sino”, 2019, No. 1, pp. 28-34.

5. Borisov S.E. Effektivnost i bezopasnost osnovannykh na ispolzovanii bedakvilina rezhimov khimioterapii u bolnykh tuberkulezom organov dykhaniya: neposredstvennye i okonchatelnye rezultaty [Efficacy and safety of bedaquiline-based chemotherapy regimens in patients with respiratory tuberculosis: immediate and final results]. Tub. i bolezni legkikh - Tub. and lung disease, 2019, Vol. 97 (5), pp. 28-42.

6. Dobrokhotova Yu.E. Vliyanie vitamina D na endometrioz [Effect of vitamin D on endometriosis]. Farmateka, 2018, No. 6 (359), pp. 84-88.

7. Inoyatova N.A. Rasprostranennost defitsita vitamina D v Respublike Tadzhikistan [Prevalence of vitamin D deficiency in the Republic of Tajikistan]. Izvestiya Akademii nauk Respubliki Tadzhikistan. Otdelenie biologicheskikh i meditsinskikh nauk - Bulletin of the Academy of Sciences of the Republic of Tajikistan. Department of Biological and Medical Sciences, 2017, No. 4 (199), pp. 80-86.

8. Kuznetsova I.V. Lechebnye i profilakticheskie effekty vitamina D pri ginekologicheskikh zabolevaniyakh, svyazannykh s izbytochnoy proliferatsiey [Therapeutic and prophylactic effects of vitamin D in gynecological diseases associated with excessive proliferation]. Akusherstvo i ginekologiya - Obstetrics and gynecology, 2018, No. 4, pp. 138-143.

9. Radzhabzoda A.S. Rukovodstvo po menedzhmentu lekarstvenno-ustoychivykh sluchaev tuberkulyoza v Respublike Tadzhikistan [Guidelines for the Management of Drug-Resistant Tuberculosis Cases in the Republic of Tajikistan]. Dushanbe, 2019. 137 p.

10. Yunusbekova M.M. Effektivnost lecheniya tuberkulyoza s shirokoy lekarstvennoy ustoychivostyu u patsientov s raznym genotipom po genam fermentov biotransformatsii CYP2B6 i NAT2 [Efficacy of treatment of extensively drug-resistant tuberculosis in patients with different genotypes of CYP2B6 and NAT2 biotransformation enzyme genes]. Tub. i bolezni lyogkikh - Tub. and lung disease, 2020, No. 6, pp. 40-42.

11. Berridge M.J. Vitamin D, reactive oxygen species and calcium signalling in ageing and disease. Philosophical Transactions of the Royal Society B, 2016, No. 371 (1700), pp. 20150434.

12. The WHO. Global Drug-resistant TB Initiative (GDI). The evaluation of effectiveness and safety of novel shorter treatment regimens for multidrug-resistant tuberculosis. Operational research protocol template. Geneva, 2018.

13. Van der Werf M. J. Eligibility for shorter treatment of multi-drug resistant tuberculosis in the European Union. European Respiratory Society, 2017, Vol. 49, No. 3, pp. 1601992.

14. The WHO Global TB Report, 2020. https://www. who.int/docs/default-source/hq-tuberculosis/global-tuberculosis-report-2020/country-profile-2020-final-web-min.pdf).